|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study demonstrates the possibility of the Biomark assay as an alternative for defining chemotherapy benefit in individual patients with ER-positive early-stage breast cancer.
|
30675242 |
2019 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Paraffin blocks obtained from patients with moderately differentiated, estrogen receptor (ER)-positive early-stage breast cancer in Switzerland, who were originally randomized to the treatment arms with and without chemotherapy in the IBCSG VIII-IX trials, were retrieved.
|
31537812 |
2019 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The 21-gene recurrence score (RS) predicts the prognosis of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer and the effectiveness of adding adjuvant chemotherapy on the basis of endocrine therapy to avoid excessive chemotherapy.
|
31186766 |
2019 |
|
Early-Stage Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Tumor tissue from patients with early stage breast cancer where ER status could be determined by both IHC and RT-PCR was included.
|
30859501 |
2019 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Their efficacy in ER(-) and early-stage breast cancer is currently under investigation.
|
31451564 |
2019 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multi-gene assays: effect on chemotherapy use, toxicity and cost in estrogen receptor-positive early stage breast cancer.
|
30663337 |
2019 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using the National Cancer Database, we identified women with T1/T2, N0, estrogen receptor-positive BC from 2009 to 2014.
|
29959613 |
2018 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adjuvant endocrine therapy (AET) is prescribed to women for 5-10 years after treatment for estrogen receptor positive (ER+ve), early-stage breast cancer.
|
30587936 |
2018 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Factors significantly associated with offering control arm treatment that were inconsistent with guidelines were time period (later trials were less likely to be consistent), breast cancer stage and type (trials in early-stage breast cancer and estrogen receptor-negative disease were less likely consistent), and recruitment in ≥4 countries and recruitment outside the United States.
|
28874598 |
2017 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We prospectively collected 227 patients with EBC with estrogen receptor-positive (ER<sup>+</sup>) and HER2<sup>-</sup> tumors.
|
28739750 |
2017 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neoadjuvant RT may significantly improve disease-free survival without reducing overall survival, especially for estrogen receptor-positive patients with early-stage breast cancer.
|
28666457 |
2017 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mounting data suggest that PIK3CA mutations or pAKT are mostly associated with better or insignificant outcomes in estrogen receptor-positive (ER+) early stage breast cancer and tend to be with worse prognosis in ER- disease. pAKT expression has been identified to predict paclitaxel chemotherapy benefit in node-positive breast cancer.
|
26995633 |
2016 |
|
Early-Stage Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Together, these data suggest that the coexpression and subsequent activity of tumor cell GR and ER contribute to the less aggressive natural history of early-stage breast cancer by coordinating the altered expression of genes favoring differentiation.
|
27141101 |
2016 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This prospective, observational, decision impact study enrolled consecutive postmenopausal patients with estrogen-receptor (ER)-positive, HER2-negative, lymph-node-negative early-stage breast cancer in 11 centers in Germany.
|
26971372 |
2016 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer.
|
26610383 |
2015 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The 21-gene Oncotype DX Recurrence Score assay is a validated assay to help decide the appropriate treatment for estrogen receptor-positive (ER+), early-stage breast cancer (EBC) in the adjuvant setting.
|
26112003 |
2015 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with ESBC with documented estrogen receptor-positive, lymph node-negative, human epidermal growth factor receptor 2-negative tumors registered within McKesson Specialty Health's iKnowMed electronic health record were included.
|
23942918 |
2013 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This economic evaluation compared genomic test-directed chemotherapy using the Oncotype DX 21-gene assay with chemotherapy for all eligible patients with lymph node-positive, estrogen receptor-positive early-stage breast cancer.
|
22138097 |
2012 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer.
|
21896991 |
2011 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
National guidelines recommend a 21-gene recurrence score (RS) to aid in adjuvant treatment decision in patients with estrogen receptor (ER)-positive, lymph node (LN)-negative early-stage breast cancer (ESBC).
|
21711071 |
2011 |
|
Early-Stage Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The decision to use adjuvant chemotherapy in patients with early stage breast cancer involves the consideration of many factors that traditionally rely heavily on tumor size and lymph node involvement and a limited set of biologic characteristics such as estrogen receptor and HER2 expression.
|
18078353 |
2007 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
|
17954712 |
2007 |